Ill-timed corneal crosslinking led to permanent changes in corneal structure in patients with keratoconus


The study evaluates three separate cases, each of which experienced irreversible changes in their corneal structure caused by challenges in getting timely treatment due to various reasons, including insurance, lost to follow up, and the COVID-19 pandemic.

Gloria B. Chiu, FAAO, FSLS, sat down with Ophthalmology Times® executive editor David Hutton to discuss her poster, "Impact of Delayed Corneal Crosslinking in Keratoconus Patients," presented at ARVO 2022 in Denver, Colorado, United States.

Video transcript

This transcript has been lightly edited for clarity.

Hi, David, thank you so much for this opportunity to be here with you today. Well, it's exciting, first of all, that ARVO was able to bring so many people back in-person to discuss research and all the exciting things we've been learning about and not able to communicate with each other over the last two years.

So my poster, as you mentioned, is titled, "Impact of Delayed Corneal Crosslinking in Keratoconus Patients." Now this poster is really only a sampling and giving us a taste of what we've been seeing in clinic, we would like to in the future share more of a case series including more patients, and the changes we saw on their eyes.

In this particular poster, my colleagues and I from the USC Roski Eye Institute in Los Angeles, discussed data from three patients. So essentially, in summary, the impact of delayed corneal crosslinking in patients who are candidates for this treatment can be very devastating.

And this was seen through these three patients. Due to various reasons, insurance being one of them, lost to follow up, and also the pandemic, we had challenges managing these patients ideally.

So because they were diagnosed with keratoconus, [and] they were young, we wanted to get them this treatment, but many of them had challenges getting insurance approval. Now, as we know, [the] FDA approved corneal crosslinking in the United States in April of 2016. So some of these patients that I was following were referred for crosslinking around that time, around 2017. Insurance coverage wasn't as good as it is now, so back then we really had challenges getting them the coverage they needed.

So we shared three cases on this poster. The first was a 26-year-old female. Essentially, she presented with keratoconus more in her left eye than the right. She had no scars in her right eye but some striae in the left eye. She was referred for crosslinking but because it wasn't covered by her insurance at that time, she couldn't get the treatment. She ended up getting fit with scleral contact lenses in 2017, but as we know the contacts didn't do anything to help the progression of the disease. So unfortunately, even though she could see better, she developed scarring. Then we kind of lost her to follow-up didn't see her back until November of 2020 when we noticed significant progression in her keratoconus. Now she had scars in both eyes, and her glasses were no longer functional. And it's been really challenging and just devastating to see the impact on her eyes and her vision, given that she's a young 20 year old.

Another case, we shared another young Caucasian male. Similarly, he had moderate keratoconus presented in 2017. And he had RGP contacts for many years. But over the years between 2017 to 2019, we followed his corneal tomographies and he looked okay, but then in 2020, when he came back we saw a significant progression. And now we saw central corneal scarring and the right eye. So with keratoconus, we look for changes through the slit lamp, such as corneal thinning, corneal striae corneal scarring. So when we saw this scarring, we referred him immediately for crosslinking. He had it done in March of 2021, in his in his right eye, and then May of 2021, in his left eye. But again, due to the pandemic, which, you know, started in about March of 2020, we weren't able to get him treated as early as we would have liked. And so we did see unfortunately steeping in his corneal topographies.

And with our last patient, he's 44. But, you know, although we generally expect keratoconus to progress in the teens and 20s, it certainly can still progress, especially if there are environmental factors such as eye rubbing. So this patient, 44-year-old, he had significant ocular allergies, floppy eye lid syndrome, and lots of eye rubbing. So he was referred for crosslinking as well, he were RGPs (rigid gas permeable lenses). He had crosslinking in one eye in his in his left eye in August of 2018. Thankfully, however, with his right eye, he had no scars. And he was referred out for improvement in his contact lens fitting, so he got Sclera Lenses, and with changes noted in his right eye later on. So he came back for his routine Scleral Lens care. But then we saw scarring in his right eye when previously we hadn't noted it. And when we sent him out for cross linking for his other eye, we again notice challenges with insurance coverage, even though he had it done in his other eye.

So these are just three instances of keratoconic patients who experienced challenges in getting timely corneal crosslinking that has led to permanent changes in their corneal structure, as well as best-corrected vision. And that's what the poster shows, with some of the images, the tomography that we have. Ultimately, we want to avoid advanced signs, such as corneal scarring, which we know will impact vision. And in our table, we just show essentially the delay these patients experienced and in our case, it wasn't just weeks or months. In some cases, it was years, because they were seen, you know, so soon after the FDA approval, and insurance coverage back then in 2017, wasn't as robust as it is today.

So we noticed changes in their prescription getting higher, decreased best-corrected vision steepening in their K measurements (their keratometry measurements), as well as thinning in their corneas. So with these changes — thinning, also, the development of scarring — these are things that cannot be reversed.

Through this poster — through these three cases — we really want to get the point out that we should initiate crosslinking as soon as possible in good candidates, particularly young individuals, and especially those with ocular allergies or who have history of eye rubbing, because these actions can lead to progression of the disease more rapidly. So particularly with the last couple of years in access to care, delays due to the pandemic, a lot of our patients unfortunately struggled with getting timely treatment; but now, hopefully moving forward once we make the proper diagnosis, and also confirm that they either have progressive keratoconus or ectasia following refractive surgery, we can get them the care they need as soon as possible.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.